Grants and awards
A new nationwide strategic plan for the Canadian Cancer Society (CCS) was formalized in 2010. This plan outlines three “Ends”, or long-term goals, that guide the mission of the CCS, including research. End 1 is focused on reducing cancer incidence; End 2 is focused on reducing cancer mortality rates; and End 3 is focused on improving the quality of life (QOL) for Canadians living with and beyond cancer. The CCS accomplishes these Ends of the organizational mission through three major activities: providing programs and services to Canadians, advocating for healthy public policies, and by funding research. Within research, our strategic priorities for the next five years are clear: to increase our focus on End 1 research, and maintain our research efforts in Ends 2 and 3. While priority areas have been identified in each of those Ends, they all include an articulated goal of supporting critical fundamental research that generates new knowledge.
The primary goal of the End 1 research strategy is to build capacity in this area of research and create a more cohesive and coordinated national risk reduction and prevention research program. Specifically, it will incorporate the CCSRI Prevention Initiative, regional division investments in cancer prevention research and various CCSRI major research initiatives, especially the Propel centre for population impact. It will provide a strong foundation for cancer prevention research and link this evidence to activities in policy development, program delivery and information to reduce cancer incidence in Canada.
The primary goal of the End 2 research strategy is to build on the considerable strengths of the biomedical/translational research community by continuing to support open investigator-initiated research. The new program is designed to support a scientific idea “pipeline” with a two-tier grant system that brackets traditional operating grants offered by CIHR and others. Specifically, the new Innovation grants program will support more innovative, creative problem solving in cancer research (high risk/high reward), while the new Impact grants program will support significant progression of research programs in the continuum from basic high impact discovery research to translational work of direct relevance to cancer patients. Continuing investment in the Clinical Trials Group (CTG) is also a major platform of our End 2 research program to reduce cancer mortality.
The primary goal of the End 3 research strategy is to bring focus to have impact in Quality of Life (QOL) research. This will be accomplished through investigator-initiated competitions in priority areas of QOL research that will be determined in consultation with the research community. The research program will emphasize knowledge translation by providing an evidence base to support delivery of the most effective programs to enhance the QOL of cancer survivors and their families. Research findings generated by major initiatives like the Clinical Trials Group (CTG) and ARCC will also be integrated into our End 3 research strategy.
Find more information about our current funding opportunities.
Learn about the programs that have ongoing funding. Note that no new applications are being accepted for these categories.
Find out how to apply for a grant.
Information about our review process and review panels.
Learn more about the committee structure of the CCSRI.
Learn the latest news on the CCSRI research program redesign.
Find competition deadline dates here.
Note: The programs and policies of the Institute are continually under review. Comments and suggestions for discussion by the CCSRI or the Advisory Committee on Research should be e-mailed to email@example.com.
Last modified on:
23 February 2012
Back to top